ID: ALA1774023

Max Phase: Preclinical

Molecular Formula: C24H27Cl2N3O2

Molecular Weight: 460.41

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(Cc1ccc(Cl)cc1)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H]1C[C@H]2CC[C@@H](C1)N2

Standard InChI:  InChI=1S/C24H27Cl2N3O2/c25-17-5-1-15(2-6-17)11-22(29-23(30)12-16-3-7-18(26)8-4-16)24(31)28-21-13-19-9-10-20(14-21)27-19/h1-8,19-22,27H,9-14H2,(H,28,31)(H,29,30)/t19-,20+,21+,22-/m1/s1

Standard InChI Key:  VYUFUXRLJDFDIC-CLAROIROSA-N

Associated Targets(Human)

Vasopressin V1a receptor 5412 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsomes 16955 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vasopressin V1b receptor 1301 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vasopressin V2 receptor 2912 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Oxytocin receptor 1962 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Caco-2 12174 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus 775804 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vasopressin V1a receptor 612 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsomes 8692 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 460.41Molecular Weight (Monoisotopic): 459.1480AlogP: 3.66#Rotatable Bonds: 7
Polar Surface Area: 70.23Molecular Species: BASEHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.26CX Basic pKa: 10.98CX LogP: 3.30CX LogD: 0.44
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.59Np Likeness Score: -0.43

References

1. Napier S, Wishart G, Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Byford A, Claxton C, Craighead M, Buchanan K, Fielding L, Gibson L, Goodwin R, Goutcher S, Irving N, MacSweeney C, Milne R, Mort C, Presland J, Sloan H, Thomson F, Turnbull Z, Young T..  (2011)  The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.,  21  (10): [PMID:21458261] [10.1016/j.bmcl.2011.02.096]
2. Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Buchanan K, Craighead M, Goodwin R, Goutcher S, Kiczun M, Lyons A, Milne R, Montgomery B, Napier S, Presland J, Sloan H, Turnbull Z, Wishart G..  (2011)  Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.,  21  (15): [PMID:21700453] [10.1016/j.bmcl.2011.05.092]

Source